Swiss drug maker Roche is full throttle in its M&A efforts, announcing 2 new deals totaling nearly $300M. Hot on the heals of it’s $43B take over offer for Genentech, the company has announced the acquisition of Mirus Bio and Canadian firm Arius Research. Favorable currency exchange rates have made many US firms attractive to foreign acquisitions and the deep pocketed Roche seems ready to spend.
Advertisement
Join the conversation as a VIP Member